Sanofi Offers Cash Buyout For Kiadis

by Vandana Singh, Benzinga Editor

February 12, 2021 6:01 AM | 1 min read | Make a Comment

Sanofi SA (NASDAQ: SNY) has launched a takeover offer for Kiadis Pharma NV KIADF to represent an aggregate adjusted equity value of €308 million. The takeover offer is priced at €5.45 per share in cash.
Kiadis’ board said it supported the offer, as it felt Sanofi’s infrastructure and capabilities would help develop Kiadis’ pipeline of products.
Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf’ NK cells from a healthy donor that seeks and identifies malignant cancer cells and has broad application across various tumor types.
The transaction was announced in November last year.
Price Action: SNY stock is down 0.8% at $47.31 in premarket on the last check Friday.